CPX-351: Phase II started

Celator said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase II trial to evaluate 2-3 dose levels of Celator’s IV CPX-351 given on days 1, 3 and 5 of each 28-day cyc...